ALBANY MOLECULAR RESEARCH INC. (AMRI) (Now Curia Global)

Company Overview

Albany Molecular Research Inc. (AMRI) was incorporated in 1991. It is a drug discovery, development, contract research and manufacturing company that works to improve patient outcomes and quality of life. The company is located in North America, Asia and Europe. The company offers technology solutions for discovery, development, analytical services, API manufacturing and drug products. AMRI employs approximately 3,100 workers via 27 locations in nine countries. With more than 1,500 clients, the company earned an estimated $570 million in 2016. High-throughput screening (HTS) offerings include numeric display readout instruments, compound and sample management, conventional and next generation HTS and informatics. These capabilities offer speed and efficiency in screening novel targets to quickly and cost effectively identify molecules.

The company’s compound and sample management capabilities include 105,000 small molecule libraries for HTS and automation sample inventory management, including compound tracking and ELN 9,000-cubic-feet, controlled-environment cold or under nitrogen storage. Other key capabilities include Labcyte Echo 555 liquid handler for high-throughput screening, Molecular Devices SpectraMax i3 multimode reader, Molecular Devices FLIPR, Essen BioScience IncuCyte ZOOM live-cell imaging system and PerkinElmer MicroBeta II. The company offers next-generation and high-resolution mass spectrometers for LC/MS/MS, including SCIEX ABI4500 QTRAP, SCIEX 6600 QTOF, HighRes Biosolutions PharmaPulse and Bruker Daltonics ultrafleXtreme MALDI-TOF/TOF. It also offers work-station-based high-throughput screening, including Tecan EVO and PerkinElmer Janus sample transfer systems and Thermo Multidrop Combis and Certus Flex bulk reagent dispensers.

AMRI’s drug metabolism and pharmacokinetics (DMPK) group delivers solutions for drug discovery. The company provides in vitro DMPK and bioanalytical/pharmacokinetic services for spanning all the stages of drug discovery (exploratory, hit-to-lead, lead optimization, candidate selection, preclinical IND-enabling studies). The company offers a wide range of assays and techniques for in vitro assessment of drug absorption, distribution, metabolism and excretion. The company uses its high-resolution SCIEX Triple TOF 6600 and SCIEX QTrap 6500 mass spectrometers and advanced software for in vitro studies.

In Dec. 2015, AMRI launched its new U.S.-based integrated drug discovery center in Buffalo, N.Y. The center offers leading-edge platforms and capabilities that help customers develop new approaches for the discovery of life-saving therapies. The center uses HTS, medicinal chemistry and pharmacology integrated within a single site in the U.S. The site aims to provide a suite of discovery services: assay development HTS, medicinal chemistry and in vitro pharmacology.

Company's Business Segments

• Drug Development Spectrum : This segment includes Contract Research, Development, Manufacturing Organization offering Products, Services across the drug development spectrum to help clients turn their ideas into real-world impact.